Home/Pipeline/Alpha-1 Antitrypsin (AAT)

Alpha-1 Antitrypsin (AAT)

Alpha-1 Antitrypsin Deficiency (AATD)

MarketedLifecycle Management

Key Facts

Indication

Alpha-1 Antitrypsin Deficiency (AATD)

Phase

Marketed

Status

Lifecycle Management

Company

Grifols

About Grifols

Grifols is a century-old global leader in plasma-derived medicines and diagnostics, operating across four core divisions: Biopharma, Diagnostics, Bio Supplies, and Hospital Healthcare Solutions. Its mission to improve health is powered by deep plasma science expertise, a robust manufacturing footprint, and significant industry recognition, including repeated honors from TIME and Forbes. The company's strategy focuses on vertical integration in plasma, geographic expansion, and scientific innovation, including exploring new therapeutic areas like neurology through its CHRONOS-PD platform.

View full company profile

Therapeutic Areas

Immunology Hematology Hepatology Intensive Care Pulmonology Neurology Infectious Diseases

Other Alpha-1 Antitrypsin Deficiency (AATD) Drugs

Drug	Company	Phase	Status
Unnamed AATD Program	AlveoGene	Pre-clinical	Lead Program
NB-101	Nerai Biosciences	Pre-clinical	Active
Undisclosed	GondolaBio	IND Enabling	Active
TSRA-196	Tessera Therapeutics	Phase 1	Active
BEAM-302 (for Beam Therapeutics)	Richmond Pharmacology	Phase 1/2	Active
KB408	Krystal Biotech	Preclinical	Active
BEAM-302	Beam Therapeutics	Phase 1/2	Active
GalNAc Program	Korro Bio	Preclinical	Active